Why Conexeu Sciences Inc.’s (CNXU) Stock Is Down 5.45%
As of Wednesday, September 02, Conexeu Sciences Inc.’s CNXU share price has dipped by 5.45%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Conexeu Sciences Inc. develops collagen-based regenerative tissue scaffold products for applications in medical aesthetics and tissue repair. The company provides patented collagen-based scaffold products, including a collagen extracellular matrix (ECM) scaffold platform for use in medical aesthetics, wound care, tissue repair, facial rejuvenation, and large-volume body contouring such as face, breast, and butt volume restoration. Its CXU collagen gel is an investigational product targeting therapeutic and aesthetic indications, supporting tissue regeneration and aiming to minimize inflammation or fibrosis. The company’s solutions are supported by preclinical and peer-reviewed data and are positioned as alternatives to conventional fillers or implants, with products currently investigational and pending regulatory clearance for certain applications. The company serves clients in the beauty, aesthetics, regenerative medicine, and medical sectors, including clinicians and professionals involved in facial rejuvenation, body contouring, wound care, and tissue repair. The company was founded in 2022 and is based in Reno, Nevada.
Commentary & Analysis
Why Conexeu Sciences Inc.’s (CNXU) Stock Is Down 9.27%
As of Tuesday, September 01, Conexeu Sciences Inc.’s CNXU share price has dipped by 9.27%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Conexeu Sciences Inc.’s (CNXU) Stock Is Down 14.84%
As of Tuesday, September 01, Conexeu Sciences Inc.’s CNXU share price has dipped by 14.84%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Conexeu Sciences Inc.’s (CNXU) Stock Is Up 6.67%
As of Thursday, August 27, Conexeu Sciences Inc.’s CNXU share price has surged by 6.67%, which has investors questioning if this is right time to sell.Michael Rose
Why Conexeu Sciences Inc.’s (CNXU) Stock Is Down 5.62%
As of Wednesday, August 26, Conexeu Sciences Inc.’s CNXU share price has dipped by 5.62%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | CNXU | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $148.8 | $288.9 | 25% |
|
| Shares Out (Mil) | 20.6 | 54.0 | 31% |
|
| Institutional Ownership | 0.3% | 93.1% | 1% |
|
| Float (Mil) | na | 41.4 | na |
|
| Beta | na | 0.94 | na |
|
| Avg Daily Volume (000s) | 286 | 480 | 51% |
|
| Price Change (52-week) |
na | 59.9% | na |
|
| Growth | CNXU | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.9% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | CNXU | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($7) | ($43) | 31% |
|
| EPS (TTM) | ($0.393) | ($1.500) | 29% |
|
| Operating Cash Flow (TTM) (Mil) | ($4) | ($31) | 26% |
|
| Net Cash Flow (TTM) (Mil) | $6 | $2 | 53% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $223 | $190 | 27% |
|
| Valuation | CNXU | Industry Median |
Percentile (All Stocks) |
|
| P/B | 16.35 | 2.84 | 94% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | CNXU | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (175.6%) | (47.7%) | 2% |
|
| ROE | (197.5%) | (55.0%) | 4% |
|
| Liabilities to Assets | 12.2% | 29.6% | 7% |
|
| F-Score | 1 | 3 | na |
|
Conexeu Sciences Inc. did not pass any screens on 9/2/2026.
